Markets:

Overview

News

Currencies

International

Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

37.41 +7.34 (+24.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Why Is Scholar Rock Holding Stock Climbing Today? ↗

November 14, 2025

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.

Via Benzinga

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗

November 14, 2025

Via Benzinga

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues ↗

September 23, 2025

Via Stocktwits

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗

November 14, 2025

Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.

Via Chartmill

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗

November 13, 2025

Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.

Via Benzinga

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

What to Expect from Scholar Rock Holding's Earnings ↗

November 13, 2025

Via Benzinga

3 Beaten-Down Stocks With Rebound Potential This Earnings Season ↗

November 12, 2025

Via MarketBeat

Alpha Buying: 3 Stocks With Sky-High Insider Confidence ↗

October 14, 2025

Via Benzinga

Why Scholar Rock Stock Got Socked on Monday ↗

October 13, 2025

The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.

Via The Motley Fool

Topics Earnings

Why Is Scholar Rock Stock Trading Lower On Monday? ↗

October 13, 2025

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Via Benzinga

Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗

October 13, 2025

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

October 13, 2025

Via Chartmill

Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 13, 2025

Via Benzinga

Why Scholar Rock Stock Raced 6% Higher Today ↗

October 09, 2025

A pundit at an influential U.S. bank is quite bullish on the company's future.

Via The Motley Fool

This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

October 09, 2025

Via Benzinga

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗

September 26, 2025

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...

Via Benzinga

Topics Stocks

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗

September 23, 2025

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Via Investor's Business Daily

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

September 22, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Why Scholar Rock Stock Bounced Higher on Monday ↗

September 15, 2025

One pundit believes the share price could rise in excess of 50%.

Via The Motley Fool

How Do Investors Really Feel About Scholar Rock Holding? ↗

September 08, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.